Background: Diffusion tensor imaging (DTI) studies have shown a widespread disruption of white matter (WM) microstructure in schizophrenia. Furthermore, higher fractional anisotropy (FA) has been consistently correlated with the severity of psychotic symptoms. Antipsychotic drugs (APDs) affect lipid homeostasis. Gene polymorphisms in sterol regulatory element binding transcription factor (SREBF)-1 and SREBF-2 have been associated with schizophrenia. Methods: In a sample of 65 patients affected by chronic schizophrenia, we investigated the effect of ongoing APD medication, SREBF-1 rs11868035 polymorphism and SREBF-2 rs1052717 polymorphism on the WM microstructure, using tract-based spatial statistics with threshold-free cluster enhancement. Results: We reported increased FA associated with the risk rs11868035 G/G genotype in several WM tracts, mainly located in the left hemisphere, and opposite effects of the APD medication load, with reduced FA and generally increased diffusivity. These opposite effects overlapped in the forceps minor, cingulum, uncinate fasciculus, the superior and inferior longitudinal fasciculi, the corticospinal tract, inferior fronto-occipital fasciculus and the anterior thalamic radiation. Conclusion: We suggest that changes of WM structure could be an as yet poorly explored biomarker of the effects of APDs, to be further investigated in prospective studies correlating long-term clinical effects with changes of DTI measures in specific WM tracts contributing to the functional integrity of the brain.

Keywords:
Schizophrenia, White matter, Sterol regulatory element binding transcription factor, Antipsychotics, Brain imaging
1.
Lee SH, DeCandia TR, Ripke S, Yang J, Sullivan PF, Goddard ME, Keller MC, Visscher PM, Wray NR: Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet 2012;44:247-250.
2.
Harrison PJ, Weinberger DR: Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005;10:40-68, image 45.
3.
Arnold SE, Trojanowski JQ: Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. Schizophr Bull 1996;22:5-9.
4.
Friston KJ, Frith CD: Schizophrenia: a disconnection syndrome? Clin Neurosci 1995;3:89-97.
5.
Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL: Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003;53:1075-1085.
6.
Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V: White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003;60:443-456.
7.
Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET: Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25.
8.
Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A: Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 2000;57:471-480.
9.
Harrison PJ: Brains at risk of schizophrenia. Lancet 1999;353:3-4.
10.
Bartzokis G: Neuroglial pharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 2012;62:2137-2153.
11.
Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S: Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003;362:798-805.
12.
Maxfield FR, Tabas I: Role of cholesterol and lipid organization in disease. Nature 2005;438:612-621.
13.
Lutton C: Dietary cholesterol, membrane cholesterol and cholesterol synthesis. Biochimie 1991;73:1327-1334.
14.
Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein JL, Wang X: SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A 1993;90:11603-11607.
15.
Rome S, Lecomte V, Meugnier E, Rieusset J, Debard C, Euthine V, Vidal H, Lefai E: Microarray analyses of SREBP-1a and SREBP-1c target genes identify new regulatory pathways in muscle. Physiol Genomics 2008;34:327-337.
16.
Le Hellard S, Muhleisen TW, Djurovic S, Ferno J, Ouriaghi Z, Mattheisen M, Vasilescu C, Raeder MB, Hansen T, Strohmaier J, Georgi A, Brockschmidt FF, Melle I, Nenadic I, Sauer H, Rietschel M, Nothen MM, Werge T, Andreassen OA, Cichon S, Steen VM: Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry 2010;15:463-472.
17.
Condra JA, Neibergs H, Wei W, Brennan MD: Evidence for two schizophrenia susceptibility genes on chromosome 22q13. Psychiatr Genet 2007;17:292-298.
18.
Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM: Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 2005;5:298-304.
19.
Raeder MB, Ferno J, Glambek M, Stansberg C, Steen VM: Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett 2006;395:185-190.
20.
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM: Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 2009;203:73-84.
21.
Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW: CNS synaptogenesis promoted by glia-derived cholesterol. Science 2001;294:1354-1357.
22.
Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM: Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(suppl 1):S208-S219.
23.
Woolrich MW, Jbabdi S, Patenaude B, Chappell M, Makni S, Behrens T, Beckmann C, Jenkinson M, Smith SM: Bayesian analysis of neuroimaging data in FSL. Neuroimage 2009;45:S173-S186.
24.
Kochunov P, Thompson PM, Lancaster JL, Bartzokis G, Smith S, Coyle T, Royall DR, Laird A, Fox PT: Relationship between white matter fractional anisotropy and other indices of cerebral health in normal aging: tract-based spatial statistics study of aging. Neuroimage 2007;35:478-487.
25.
Herting MM, Maxwell EC, Irvine C, Nagel BJ: The impact of sex, puberty, and hormones on white matter microstructure in adolescents. Cereb Cortex 2012;22:1979-1992.
26.
Engvig A, Fjell AM, Westlye LT, Moberget T, Sundseth O, Larsen VA, Walhovd KB: Memory training impacts short-term changes in aging white matter: a longitudinal diffusion tensor imaging study. Hum Brain Mapp 2012;33:2390-2406.
27.
Samartzis L, Dima D, Fusar-Poli P, Kyriakopoulos M: White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies. J Neuroimaging 2014;24:101-110.
28.
Smith SM, Nichols TE: Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44:83-98.
29.
Ellison-Wright I, Bullmore E: Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009;108:3-10.
30.
Alba-Ferrara LM, de Erausquin GA: What does anisotropy measure? Insights from increased and decreased anisotropy in selective fiber tracts in schizophrenia. Front Integr Neurosci 2013;7:9.
31.
Mulert C, Kirsch V, Whitford TJ, Alvarado J, Pelavin P, McCarley RW, Kubicki M, Salisbury DF, Shenton ME: Hearing voices: a role of interhemispheric auditory connectivity? World J Biol Psychiatry 2012;13:153-158.
32.
Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, Maier SE, Schroth G, Lovblad K, Dierks T: Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry 2004;61:658-668.
33.
Rotarska-Jagiela A, Oertel-Knoechel V, DeMartino F, van de Ven V, Formisano E, Roebroeck A, Rami A, Schoenmeyer R, Haenschel C, Hendler T, Maurer K, Vogeley K, Linden DE: Anatomical brain connectivity and positive symptoms of schizophrenia: a diffusion tensor imaging study. Psychiatry Res 2009;174:9-16.
34.
Shergill SS, Kanaan RA, Chitnis XA, O'Daly O, Jones DK, Frangou S, Williams SC, Howard RJ, Barker GJ, Murray RM, McGuire P: A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry 2007;164:467-473.
35.
Seok JH, Park HJ, Chun JW, Lee SK, Cho HS, Kwon JS, Kim JJ: White matter abnormalities associated with auditory hallucinations in schizophrenia: a combined study of voxel-based analyses of diffusion tensor imaging and structural magnetic resonance imaging. Psychiatry Res 2007;156:93-104.
36.
Cheung V, Chiu CP, Law CW, Cheung C, Hui CL, Chan KK, Sham PC, Deng MY, Tai KS, Khong PL, McAlonan GM, Chua SE, Chen E: Positive symptoms and white matter microstructure in never-medicated first episode schizophrenia. Psychol Med 2011;41:1709-1719.
37.
Filippi M, Canu E, Gasparotti R, Agosta F, Valsecchi P, Lodoli G, Galluzzo A, Comi G, Sacchetti E: Patterns of brain structural changes in first-contact, antipsychotic drug-naive patients with schizophrenia. AJNR Am J Neuroradiol 2014;35:30-37.
38.
Pierpaoli C, Barnett A, Pajevic S, Chen R, Penix LR, Virta A, Basser P: Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage 2001;13:1174-1185.
39.
Rose SE, Hatzigeorgiou X, Strudwick MW, Durbridge G, Davies PS, Colditz PB: Altered white matter diffusion anisotropy in normal and preterm infants at term-equivalent age. Magn Reson Med 2008;60:761-767.
40.
Chao TC, Chou MC, Yang P, Chung HW, Wu MT: Effects of interpolation methods in spatial normalization of diffusion tensor imaging data on group comparison of fractional anisotropy. Magn Reson Imaging 2009;27:681-690.
41.
Hoeft F, Barnea-Goraly N, Haas BW, Golarai G, Ng D, Mills D, Korenberg J, Bellugi U, Galaburda A, Reiss AL: More is not always better: increased fractional anisotropy of superior longitudinal fasciculus associated with poor visuospatial abilities in Williams syndrome. J Neurosci 2007;27:11960-11965.
42.
Benedetti F, Yeh PH, Bellani M, Radaelli D, Nicoletti MA, Poletti S, Falini A, Dallaspezia S, Colombo C, Scotti G, Smeraldi E, Soares JC, Brambilla P: Disruption of white matter integrity in bipolar depression as a possible structural marker of illness. Biol Psychiatry 2011;69:309-317.
43.
Hurley RA, Taber KH: Windows to the Brain: Insights from Neuroimaging. Washington, American Psychiatric Publishing, 2008.
44.
Ashtari M, Cervellione KL, Hasan KM, Wu J, McIlree C, Kester H, Ardekani BA, Roofeh D, Szeszko PR, Kumra S: White matter development during late adolescence in healthy males: a cross-sectional diffusion tensor imaging study. Neuroimage 2007;35:501-510.
45.
O'Daly OG, Frangou S, Chitnis X, Shergill SS: Brain structural changes in schizophrenia patients with persistent hallucinations. Psychiatry Res 2007;156:15-21.
46.
Honea R, Crow TJ, Passingham D, Mackay CE: Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005;162:2233-2245.
47.
Walterfang M, Wood AG, Reutens DC, Wood SJ, Chen J, Velakoulis D, McGorry PD, Pantelis C: Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness. Br J Psychiatry 2008;192:429-434.
48.
Cheung V, Cheung C, McAlonan GM, Deng Y, Wong JG, Yip L, Tai KS, Khong PL, Sham P, Chua SE: A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia. Psychol Med 2008;38:877-885.
49.
Bora E, Fornito A, Radua J, Walterfang M, Seal M, Wood SJ, Yucel M, Velakoulis D, Pantelis C: Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res 2011;127:46-57.
50.
Sexton CE, Mackay CE, Lonie JA, Bastin ME, Terriere E, O'Carroll RE, Ebmeier KP: MRI correlates of episodic memory in Alzheimer's disease, mild cognitive impairment, and healthy aging. Psychiatry Res 2010;184:57-62.
51.
Kristiana I, Sharpe LJ, Catts VS, Lutze-Mann LH, Brown AJ: Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J 2010;10:396-407.
52.
Liscum L, Faust JR: The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one. J Biol Chem 1989;264:11796-11806.
53.
Lange Y, Steck TL: Cholesterol homeostasis. Modulation by amphiphiles. J Biol Chem 1994;269:29371-29374.
54.
Ferno J, Skrede S, Vik-Mo AO, Havik B, Steen VM: Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 2006;7:69.
55.
Adams CM, Goldstein JL, Brown MS: Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci U S A 2003;100:10647-10652.
56.
Ness GC: Developmental regulation of the expression of genes encoding proteins involved in cholesterol homeostasis. Am J Med Genet 1994;50:355-357.
57.
Dietschy JM, Turley SD: Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375-1397.
58.
Barres BA, Smith SJ: Cholesterol - making or breaking the synapse. Science 2001;294:1296-1297.
59.
Bartzokis G: Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments. Front Biosci (Landmark Ed) 2011;16:2695-2733.
60.
Mathai JC, Tristram-Nagle S, Nagle JF, Zeidel ML: Structural determinants of water permeability through the lipid membrane. J Gen Physiol 2008;131:69-76.
61.
Gallo V: Surprising synapses deep in the brain. Nat Neurosci 2007;10:267-269.
62.
Kukley M, Capetillo-Zarate E, Dietrich D: Vesicular glutamate release from axons in white matter. Nat Neurosci 2007;10:311-320.
63.
Ziskin JL, Nishiyama A, Rubio M, Fukaya M, Bergles DE: Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 2007;10:321-330.
64.
Karadottir R, Attwell D: Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 2007;145:1426-1438.
65.
Peters A: The effects of normal aging on myelinated nerve fibers in monkey central nervous system. Front Neuroanat 2009;3:11.
66.
Werner HB, Kramer-Albers EM, Strenzke N, Saher G, Tenzer S, Ohno-Iwashita Y, De Monasterio-Schrader P, Mobius W, Moser T, Griffiths IR, Nave KA: A critical role for the cholesterol-associated proteolipids PLP and M6B in myelination of the central nervous system. Glia 2013;61:567-586.
67.
Benedetti F, Poletti S, Radaelli D, Pozzi E, Giacosa C, Ruffini C, Falini A, Smeraldi E: Caudate gray matter volume in obsessive-compulsive disorder is influenced by adverse childhood experiences and ongoing drug treatment. J Clin Psychopharmacol 2012;32:544-547.
68.
Yoo SY, Jang JH, Shin YW, Kim DJ, Park HJ, Moon WJ, Chung EC, Lee JM, Kim IY, Kim SI, Kwon JS: White matter abnormalities in drug-naive patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment. Acta Psychiatr Scand 2007;116:211-219.
69.
Bakhti M, Winter C, Simons M: Inhibition of myelin membrane sheath formation by oligodendrocyte-derived exosome-like vesicles. J Biol Chem 2011;286:787-796.
70.
Bartzokis G, Lu PH, Heydari P, Couvrette A, Lee GJ, Kalashyan G, Freeman F, Grinstead JW, Villablanca P, Finn JP, Mintz J, Alger JR, Altshuler LL: Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals. Biol Psychiatry 2012;72:1026-1034.
71.
Andreasen NC, Liu D, Ziebell S, Vora A, Ho BC: Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013;170:609-615.
72.
Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 2008;63:759-765.
73.
Segatto M, Di Giovanni A, Marino M, Pallottini V: Analysis of the protein network of cholesterol homeostasis in different brain regions: an age and sex dependent perspective. J Cell Physiol 2013;228:1561-1567.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.